

Revision date: 05-Jan-2007 Version: 1.1 Page 1 of 6

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Trade Name: KELFIPRIM®; TRIDIS®

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as antibiotic agent

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Maize starch	9005-25-8	232-679-6	*
Talc (non-asbestiform)	14807-96-6	238-877-9	*
Trimethoprim	738-70-5	212-006-2	50
Magnesium Stearate	557-04-0	209-150-3	*
Sulfadiazine	68-35-9	200-685-8	40

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safetv.

3. HAZARDS IDENTIFICATION

Appearance: Gray and yellow capsules

Signal Word: WARNING

Statement of Hazard: Harmful if swallowed.

Possible risk of harm to the unborn child

Additional Hazard Information:

Short Term: May be harmful if swallowed. (based on animal data).

Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: Adverse effects associated with the therapeutic use include nausea diarrhea

Adverse effects associated with the therapeutic use include nausea diarrhea blood cell changes muscle pain skin rash Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis) kidney toxicity (nephrotoxicity) Clinical use has resulted in changes in electrolytes and/or blood chemistry changes. Individuals sensitive to this material or other

materials in its chemical class may develop allergic reactions.

EU Indication of danger: Toxic

Toxic to Reproduction; Category 3

EU Hazard Symbols:

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Revision date: 05-Jan-2007 Version: 1.1



EU Risk Phrases:

R25 - Toxic if swallowed.

R63 - Possible risk of harm to the unborn child.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

Page 2 of 6

workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get

medical attention.

Skin Contact: Remove clothing and wash affected skin with soap and water. If irritation occurs or persists,

get medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never

give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits fumes of carbon dioxide sulfur oxides nitrogen oxides

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Page 3 of 6

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Revision date: 05-Jan-2007 Version: 1.1

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with

eyes, skin, and clothing.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Maize starch

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total

ACGIH Threshold Limit Value (TWA) = 5 mg/m³ TWA Australia TWA = 10 mg/m³ TWA = 10 mg/m³ TWA

Talc (non-asbestiform)

OSHA - Final PELs - Table Z-3 Mineral D: = 20 mppcf TWA
ACGIH Threshold Limit Value (TWA) = 2 mg/m³ TWA

Australia TWA = 2.5 mg/m³ TWA containing no asbestos fibers

Trimethoprim

Pfizer OEL TWA-8 Hr: 0.1mg/m³

Magnesium Stearate

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA except stearates of toxic metals

Australia TWA = 10 mg/m³ TWA

Sulfadiazine

Pfizer OEL TWA-8 Hr: 2 mg/m³

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Analytical Method: Analytical method available for sulfadiazine; trimethoprin. Contact Pfizer Inc for further

information.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with

large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is

possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with

large quantities.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit

(OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control

exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Capsule Color: Gray and yellow

Molecular Formula: Mixture Molecular Weight: Mixture

Page 4 of 6

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Revision date: 05-Jan-2007 Version: 1.1

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: None known

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Trimethoprim

Rat Oral LD50 200 mg/kg

LD50 500 mg/kg Rat Intraperitoneal Mouse Oral LD50 2764 mg/kg Mouse Intravenous LD50 200 mg/kg Mouse Intraperitoneal LD50 1870 mg/kg

Sulfadiazine

Mouse Oral LD 50 1500 mg/kg

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Trimethoprim

Reproductive & Fertility-Males Rat Oral 70 mg/kg/day **NOAEL** Fertility Reproductive & Fertility - Females Rat Oral 14 mg/kg/day **NOAEL** Fertility Embryo / Fetal Development Rabbit Oral 30 mg/kg LOAEL **Embryotoxicity**

Embryo / Fetal Development Rat Oral 200 mg/kg LOAEL Maternal Toxicity, Teratogenic

Embryo / Fetal Development Mouse Oral 70 mg/kg NOAEL Not Teratogenic

Sulfadiazine

NOEL Embryo / Fetal Development Oral 500 mg/kg/day Not teratogenic Rat Embryo / Fetal Development Oral **NOEL** Mouse 500 mg/kg/day Not Teratogenic Reproductive & Fertility Rabbit 250 mg/kg/day NOEL Not Teratogenic Oral

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Trimethoprim

Bacterial Mutagenicity (Ames) Salmonella , E. coli Negative

In Vitro Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative

In Vitro Chromosome Aberration Human Lymphocytes Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

See below

Page 5 of 6

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Revision date: 05-Jan-2007 Version: 1.1

Talc (non-asbestiform)

IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol:

EU Indication of danger: Toxic

Toxic to Reproduction; Category 3

EU Risk Phrases:

R25 - Toxic if swallowed.

R63 - Possible risk of harm to the unborn child.

EU Safety Phrases:

S22 - Do not breathe dust.

S28 - After contact with skin, wash immediately with plenty of water.

S36/37 - Wear suitable protective clothing and gloves.

S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label

where possible).

S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:

WARNING

Harmful if swallowed.

Possible risk of harm to the unborn child

Canada - WHMIS: Classifications

Page 6 of 6

Material Name: Trimethoprim/Sulfametopyrazine Capsules

Revision date: 05-Jan-2007 Version: 1.1

WHMIS hazard class:

Class D, Division 1, Subdivision B Class D. Division 2. Subdivision A



Maize starch

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-679-6

Talc (non-asbestiform)

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentEU EINECS List238-877-9

Trimethoprim

Australia (AICS): Present
Standard for the Uniform Scheduling Schedule 4

for Drugs and Poisons:

EU EINECS List 212-006-2

Magnesium Stearate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS List

209-150-3

Sulfadiazine

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentStandard for the Uniform SchedulingSchedule 4for Drugs and Poisons:Schedule 5EU EINECS List200-685-8

16. OTHER INFORMATION

Reasons for Revision: Updated Section 3 - Hazard Identification. Updated Section 5 - Fire Fighting Measures.

Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 13 -

Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet